Blog
    Regulatory UpdateFor PhysiciansOctober 20, 2026

    Semaglutide and Peptide Regulatory Update: FDA Status and Safety

    Review recent FDA regulatory shifts for semaglutide and BPC-157, plus a summary of FAERS safety signals and compounding status as of late 2026.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    What is the current regulatory status and safety profile of frequently utilized peptides, including semaglutide and substances recently reviewed by the FDA Pharmacy Compounding Advisory Committee (PCAC)?

    Evidence Snapshot

    • Semaglutide: FDA-approved (Ozempic, Wegovy, Rybelsus); 503B exclusion proposed Sept 2026.
    • BPC-157: Category 2 (Sept 2023); PCAC review completed July 2026 regarding Bulks List inclusion.
    • KPV: Nomination withdrawn; PCAC review conducted July 2026.
    • Safety Signals: Emerging FAERS signals for semaglutide include NAION (Eye) and pulmonary aspiration.
    • Warning Letters: Multiple agents (GHRP-2, GHRP-6, Melanotan II) received 2020 warning letters regarding compounding practices.

    What the Research Shows

    Regulatory Status and Compounding Restrictions As of September 2026, the regulatory landscape for peptide compounding has shifted significantly. For semaglutide, the national shortage-related enforcement discretion for compounding has ended. While patient-specific compounding remains under Section 503A, it is subject to restrictions against regularly producing copies of commercially available drugs. The FDA has proposed excluding semaglutide from the 503B Bulks List due to a lack of identified clinical need. Furthermore, the FDA has clarified that semaglutide sodium and semaglutide acetate are not the same active ingredients as those in approved products and lacks a known lawful basis for compounding.

    For non-approved substances, the FDA has utilized Category 2 classifications for substances presenting significant safety risks. BPC-157 was placed in Category 2 in September 2023 due to concerns regarding immunogenicity and limited human safety data. Its status evolved with a Pharmacy Compounding Advisory Committee (PCAC) review in July 2026. Similarly, KPV, which was previously in Category 2 before its nomination was withdrawn, underwent PCAC review in July 2026 for potential inclusion on the 503A Bulks List.

    Other peptides remain heavily restricted. GHRP-2 and GHRP-6 are currently listed as Category 2 (Sept 2023) due to immunogenicity concerns. Melanotan II is categorized similarly following reports of multiple serious adverse events and safety warnings from the FDA and TGA.

    Safety Signals and Adverse Event Monitoring Data from the FDA Adverse Event Reporting System (FAERS) for semaglutide shows a high volume of reports, totaling 187,757 GLP-1 RA reports through 2023. While gastrointestinal effects like nausea, vomiting, and delayed gastric emptying are well-documented in product labeling, new signals have emerged.

    Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) is an emerging signal with 96 cases detected through December 2024, leading to a formal EMA review in January 2025. Pulmonary aspiration has also been added to the Ozempic label (2025) as a risk during general anesthesia due to delayed gastric emptying. Other labeled concerns under monitoring include acute kidney injury, pancreatitis, and cholelithiasis.

    Mechanism

    Mechanistic data for these agents varies by classification:

    • Semaglutide: Functions as a GLP-1 receptor agonist; its safety profile is impacted by its effect on delayed gastric emptying.
    • MK-677: Identified as a non-peptide growth hormone (GH) secretagogue.
    • Regulatory Concerns: The primary mechanism of safety concern cited by the FDA for BPC-157, GHRP-2, and GHRP-6 is immunogenicity.

    Limitations of the Evidence

    A primary limitation for several substances, including bpc-157 and KPV, is the lack of human safety information and API characterization. Regulatory records indicate that for these agents, there is significant uncertainty regarding peptide-related impurities. While clinical trials for semaglutide are robust—showing 14.9% weight loss in STEP 1 and 20% MACE reduction in SELECT—emerging safety signals like NAION require further longitudinal data to establish definitive causality.

    Clinical Takeaway

    Regulatory oversight of peptides has intensified, with the FDA ending shortage-based compounding for semaglutide and reviewing numerous other peptides (BPC-157, KPV) for safety risks. Clinicians should note emerging safety signals for GLP-1 RAs, particularly regarding perioperative aspiration risks and NAION, while recognizing that many other peptides remain in Category 2 due to immunogenicity and a lack of human data.

    For clinicians seeking to navigate these regulatory changes, consulting a specialized peptide doctor may provide additional context on current compounding availability. You can locate qualified providers at peptide-therapy-near-me.

    Sources

    • FDA: Certain bulk drug substances that may present significant safety risks (Sept 2023)
    • FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting
    • FDA: Medications containing semaglutide marketed for type 2 diabetes or weight loss
    • FAERS Database: Semaglutide Safety Signals (2023-2025)
    • FDA: Bulk drug substances used in compounding (Sept 2026)
    • FDA Clarification: GLP-1 Supply and Compounding Policies (2026)

    Referenced Peptides

    semaglutidebpc 157ghrp 2ghrp 6

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.